Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in
patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis
and aquaporin-4-seropositive neuromyelitis optica spectrum disorder. Based on an
extensive literature review and a structured consensus process, we propose diagnostic
criteria for MOG antibody-associated disease (MOGAD) in which the presence of MOG-IgG
is a core criterion. According to our proposed criteria, MOGAD is typically associated with …

Patients with Myelin Oligodendrocyte Glycoprotein (MOG)-IgG present with isolated optic
neuritis or transverse myelitis, acute disseminated encephalomyelitis (ADEM), brainstem or
cerebellar features, or cerebral cortical encephalitis. Unlike Multiple Sclerosis (MS) and
AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD), in which
multiple clinical attacks characterize relapsing forms of the disease, individuals with MOG
antibody-associated disease (MOGAD) can have either a monophasic or relapsing course …